News
LXRX
0.7886
+1.48%
0.0115
Executive reshuffles: WELL, SLG and LXRX
Seeking Alpha · 6h ago
Lexicon Pharmaceuticals Appoints New CFO Scott M. Coiante
TipRanks · 2d ago
Lexicon Pharmaceuticals Names Scott Coiante Finance Chief
Dow Jones · 2d ago
Press Release: Lexicon Appoints Scott Coiante as Chief Financial Officer
Dow Jones · 2d ago
*Lexicon Appoints Scott Coiante as Chief Financial Officer >LXRX
Dow Jones · 2d ago
Weekly Report: what happened at LXRX last week (1223-1227)?
Weekly Report · 12/30/2024 09:21
BUZZ-U.S. STOCKS ON THE MOVE-Walmart, Fiserv, Rumble
Reuters · 12/23/2024 18:43
BUZZ-U.S. STOCKS ON THE MOVE-Nordstrom, Optical Cable, Lexicon
Reuters · 12/23/2024 16:19
LEXICON PHARMACEUTICALS SHARES FALL 9% AFTER FDA DECLINES TO APPROVE ITS ADD-ON DIABETES DRUG
Reuters · 12/23/2024 14:32
BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Playa Hotels, Rumble
Reuters · 12/23/2024 14:24
BUZZ-Lexicon Pharma falls after FDA declines to approve its add-on diabetes drug
Reuters · 12/23/2024 12:02
Analyst Expectations For Lexicon Pharmaceuticals's Future
Benzinga · 12/23/2024 12:00
Needham Reiterates Hold on Lexicon Pharmaceuticalsto Hold
Benzinga · 12/23/2024 11:56
Needham Remains a Hold on Lexicon Pharmaceuticals (LXRX)
TipRanks · 12/23/2024 11:55
Weekly Report: what happened at LXRX last week (1216-1220)?
Weekly Report · 12/23/2024 09:23
Stocks to Watch: Rumble, Lexicon Pharmaceuticals
Dow Jones · 12/20/2024 23:19
FDA rejects Lexicon's Zynquista for diabetes, kidney disease
Seeking Alpha · 12/20/2024 22:30
Lexicon Receives Complete Response Letter from FDA for Diabetes, Kidney Disease Treatment
Dow Jones · 12/20/2024 22:03
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
Reuters · 12/20/2024 21:40
Lexicon receives CRL for Zynquista
TipRanks · 12/20/2024 21:35
More
Webull provides a variety of real-time LXRX stock news. You can receive the latest news about Lexicon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.